RhThrombin
RhThrombin Uses, Dosage, Side Effects, Food Interaction and all others data.
RhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery. ZymoGenetics is developing RhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery. Thrombin is used in more than 1 million surgeries each year in the United States. Currently, only thrombin derived from bovine blood is available in the U.S. as a stand-alone thrombin product. Bovine-derived thrombin has been associated with the development of antibodies that may cross-react with human blood proteins and in some cases these antibodies appear to be related to serious bleeding complications. The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand.
Plasma-derived bovine thrombin is used as a topical agent to improve surgical hemostasis, but development of antibodies to bovine hemostatic proteins has been associated with increased bleeding and thrombotic complications. RhThrombin has a superior immunogenicity profile compared with bovine thrombin (1.5% versus 22%, respectively, p<0.0001; antibodies developed to the products, as defined by seroconversion or significant change in titer units). Characterization of the binding antibodies demonstrated none of the anti-RhThrombin antibodies neutralized human plasma thrombin.
| Trade Name | RhThrombin |
| Generic | rhThrombin |
| rhThrombin Other Names | Recombinant thrombin, Recothrom, rhThrombin, rThrombin |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in blood (blood forming organ disorders, unspecified) and hemorrhage.
How RhThrombin works
The potent hemostatic properties of thrombin derive from its ability to activate platelets directly to aggregate and adhere to damaged vessels and to catalyze the formation simultaneously of a fibrin matrix. Application of exogenous thrombin bypasses the physiological process of generating a thrombin burst by directly initiating the terminal reactions of blood clot formation. RhThrombin rapidly binds to endogenous inhibitors following either i.v. or s.c. administration.
Half Life
Approximately 15 hours (measured in non-human primates).
Innovators Monograph
You find simplified version here RhThrombin
